FDA safety warnings and trends in testosterone marketing to physicians

In this study, we found that testosterone marketing efforts such as marketing spending per encounter, quarterly marketing spending per physician, and quarterly number of encounters per physician increased among non-PCPs and urban physicians for 4 quarters following an FDA boxed warning in 2015 on testosterone prescriptions. After the black box warning, off-label testosterone advertisements stopped. This reduction in advertising could have made it more attractive for pharmaceutical companies to increase their marketing spending targeting non-PCPs and physicians in urban areas. Understanding responses of pharmaceutical companies to FDA guidelines is important and can help inform future guideline initiatives.PMID:35404550 | DOI:10.37765/ajmc.2022.88841

Source: The American Journal of Managed Care - April 11, 2022 Category: Health Management Authors: Adeniyi Togun Ashwini Sankar Pinar Karaca-Mandic Source Type: research